Acquired Company

Jade Biosciences completed its merger with Aerovate Therapeutics on April 28, 2025, and will operate under the name Jade Biosciences, trading on Nasdaq under the ticker JBIO.

Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Show more

Location: 930 Winter Street, Waltham, MA, 02451, United States | Website: https://www.aerovatetx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

77.68M

52 Wk Range

$2.63 - $884.98

Previous Close

$15.64

Open

$15.59

Volume

136,238

Day Range

$14.90 - $15.96

Enterprise Value

1.782M

Cash

76.21M

Avg Qtr Burn

-12.48M

Insider Ownership

0.02%

Institutional Own.

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AV-101 Details Pulmonary arterial hypertension	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.

We track quarterly 13F filings for some of the largest biotech hedge funds here.